US regulatory status: approved. Molecular target: Fatty-acid amide hydrolase 1.
- Target
- Fatty-acid amide hydrolase 1
- Mechanism
- Cyclooxygenase inhibitor
pharma · Urea cycle disorders (UCD) · Cannabis Smoking · CAMP
Camp4 Therapeutics
Camp4 Therapeutics Corp
Camp4 Therapeutics drug portfolio — 15 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Cambridge, USA HQ
2016 Founded
60 Employees
Public company Type
CAMP · NYSE Ticker
Company details
- Status
- Public
- HQ
- Cambridge, USA
- Founded
- 2016
- Employees
- 60
- Programs
- 9
- Drugs
- 15
- Patents
- 4
Camp4 Therapeutics pipeline
Portfolio lens on 15 drugs and development assets — regulatory status, targets, and deep links to NovaPharmaNews drug profiles.
Camp4 Therapeutics drug portfolio — 15 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Drug portfolio
-
-
Development asset linked to Camp4 Therapeutics in public FDA and regional records.
-
Development asset linked to Camp4 Therapeutics in public FDA and regional records.
-
Development asset linked to Camp4 Therapeutics in public FDA and regional records.
-
Development asset linked to Camp4 Therapeutics in public FDA and regional records.
-
US regulatory status: approved. Molecular target: Synaptosomal-associated protein 25.
- Target
- Synaptosomal-associated protein 25
- Mechanism
- Synaptosomal-associated protein 25 inhibitor
-
Development asset linked to Camp4 Therapeutics in public FDA and regional records.
-
US regulatory status: approved. Molecular target: Glutamate [NMDA] receptor.
- Target
- Glutamate [NMDA] receptor
- Mechanism
- Glutamate [NMDA] receptor negative allosteric modulator
-
Development asset linked to Camp4 Therapeutics in public FDA and regional records.
-
US regulatory status: approved.
-
US regulatory status: approved.
-
Development asset linked to Camp4 Therapeutics in public FDA and regional records.
-
Development asset linked to Camp4 Therapeutics in public FDA and regional records.
-
US regulatory status: approved.
-
Development asset linked to Camp4 Therapeutics in public FDA and regional records.